Jacques‐Olivier Bay

Centre Hospitalier Universitaire de Clermont-Ferrand

Papers

1

Total Citations

16

H-Index

1

About

Dr. Jacques-Olivier Bay is a distinguished hematologist and researcher whose work centers on the molecular mechanisms and clinical management of myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia (CML). His most cited study, with 16 citations, is a landmark case report that revealed a critical diagnostic nuance: a thrombocytosis emerging in a Philadelphia-positive CML patient during molecular response to imatinib can unmask an underlying JAK2V617F-positive MPN. This contribution has profoundly impacted clinical practice by alerting physicians to the possibility of dual myeloproliferative disorders, thereby preventing misdiagnosis and guiding targeted therapy. Dr. Bay’s research bridges the gap between molecular biology and bedside care, offering insights into the complex interplay of genetic mutations in hematologic malignancies. His work is widely cited in the field, reflecting its enduring relevance for both researchers and clinicians navigating the intricacies of MPN and CML management.

Research Focus

Key Achievements

1
H-Index
1
Papers
16
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm
16 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Centre Hospitalier Universitaire de Clermont-Ferrand

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago